Literature DB >> 29742798

Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.

Harneet Arora1, Rebecca J Willcocks1, Donovan J Lott1, Ann T Harrington2, Claudia R Senesac1, Kirsten L Zilke3, Michael J Daniels4, Dandan Xu5, Gihan I Tennekoon2, Erika L Finanger3, Barry S Russman3, Richard S Finkel6, William T Triplett1, Barry J Byrne7, Glenn A Walter8, H Lee Sweeney9, Krista Vandenborne1.   

Abstract

INTRODUCTION: Tests of ambulatory function are common clinical trial endpoints in Duchenne muscular dystrophy (DMD). Using these tests, the ImagingDMD study has generated a large data set that can describe the contemporary natural history of DMD in 5-12.9-year-olds.
METHODS: Ninety-two corticosteroid-treated boys with DMD and 45 controls participated in this longitudinal study. Participants performed the 6-minute walk test (6MWT) and timed function tests (TFT: 10-m walk/run, climbing 4 stairs, supine to stand).
RESULTS: Boys with DMD had impaired functional performance even at 5-6.9 years old. Boys older than 7 had significant declines in function over 1 year for 10-m walk/run and 6MWT. Eighty percent of participants could perform all functional tests at 9 years old. TFTs appear to be slightly more responsive and predictive of disease progression than the 6MWT in 7-12.9 year olds. DISCUSSION: This study provides insight into the contemporary natural history of key functional endpoints in DMD. Muscle Nerve 58: 631-638, 2018.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  6-minute walk test; Duchenne muscular dystrophy; ambulatory function; functional endpoints; loss of ambulation; outcome measures

Mesh:

Year:  2018        PMID: 29742798      PMCID: PMC6660165          DOI: 10.1002/mus.26161

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  27 in total

1.  Management of progressive muscular dystrophy in childhood.

Authors:  P J VIGNOS; G E SPENCER; K C ARCHIBALD
Journal:  JAMA       Date:  1963-04-13       Impact factor: 56.272

2.  Evidence-based path to newborn screening for Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Chris Shilling; Nancy D Leslie; Kevin M Flanigan; Roula al-Dahhak; Julie Gastier-Foster; Kelley Kneile; Diane M Dunn; Brett Duval; Alexander Aoyagi; Cindy Hamil; Maha Mahmoud; Kandice Roush; Lauren Bird; Chelsea Rankin; Heather Lilly; Natalie Street; Ram Chandrasekar; Robert B Weiss
Journal:  Ann Neurol       Date:  2012-03       Impact factor: 10.422

3.  Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS.

Authors:  Ishu Arpan; Rebecca J Willcocks; Sean C Forbes; Richard S Finkel; Donovan J Lott; William D Rooney; William T Triplett; Claudia R Senesac; Michael J Daniels; Barry J Byrne; Erika L Finanger; Barry S Russman; Dah-Jyuu Wang; Gihan I Tennekoon; Glenn A Walter; H L Sweeney; Krista Vandenborne
Journal:  Neurology       Date:  2014-08-06       Impact factor: 9.910

Review 4.  Duchenne muscular dystrophy: clinical trials and emerging tribulations.

Authors:  Perry B Shieh
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

Review 5.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

Review 6.  Population frequencies of inherited neuromuscular diseases--a world survey.

Authors:  A E Emery
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

7.  Exon-skipping therapy: a roadblock, detour, or bump in the road?

Authors:  Eric P Hoffman; Elizabeth M McNally
Journal:  Sci Transl Med       Date:  2014-04-02       Impact factor: 17.956

8.  Ataluren treatment of patients with nonsense mutation dystrophinopathy.

Authors:  Katharine Bushby; Richard Finkel; Brenda Wong; Richard Barohn; Craig Campbell; Giacomo P Comi; Anne M Connolly; John W Day; Kevin M Flanigan; Nathalie Goemans; Kristi J Jones; Eugenio Mercuri; Ros Quinlivan; James B Renfroe; Barry Russman; Monique M Ryan; Mar Tulinius; Thomas Voit; Steven A Moore; H Lee Sweeney; Richard T Abresch; Kim L Coleman; Michelle Eagle; Julaine Florence; Eduard Gappmaier; Allan M Glanzman; Erik Henricson; Jay Barth; Gary L Elfring; Allen Reha; Robert J Spiegel; Michael W O'donnell; Stuart W Peltz; Craig M Mcdonald
Journal:  Muscle Nerve       Date:  2014-10       Impact factor: 3.217

9.  The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year.

Authors:  Erik Henricson; Richard Abresch; Jay J Han; Alina Nicorici; Erica Goude Keller; Evan de Bie; Craig M McDonald
Journal:  PLoS Curr       Date:  2013-07-08

10.  The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Julaine Florence; Michelle Eagle; Eduard Gappmaier; Allan M Glanzman; Robert Spiegel; Jay Barth; Gary Elfring; Allen Reha; Stuart W Peltz
Journal:  Muscle Nerve       Date:  2013-07-17       Impact factor: 3.217

View more
  19 in total

1.  Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.

Authors:  Daniela J Conrado; Jane Larkindale; Alexander Berg; Micki Hill; Jackson Burton; Keith R Abrams; Richard T Abresch; Abby Bronson; Douglass Chapman; Michael Crowther; Tina Duong; Heather Gordish-Dressman; Lutz Harnisch; Erik Henricson; Sarah Kim; Craig M McDonald; Stephan Schmidt; Camille Vong; Xiaoxing Wang; Brenda L Wong; Florence Yong; Klaus Romero
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-24       Impact factor: 2.745

2.  12-Month progression of motor and functional outcomes in congenital myotonic dystrophy.

Authors:  Kellen H Quigg; Kiera N Berggren; Melissa McIntyre; Kameron Bates; Francesca Salmin; Jacopo L Casiraghi; Adele DʼAmico; Guja Astrea; Federica Ricci; Marnee J McKay; Jennifer N Baldwin; Joshua Burns; Craig Campbell; Valeria A Sansone; Nicholas E Johnson
Journal:  Muscle Nerve       Date:  2021-01-10       Impact factor: 3.217

3.  Walking activity in a large cohort of boys with Duchenne muscular dystrophy.

Authors:  Donovan J Lott; Tanja Taivassalo; Claudia R Senesac; Rebecca J Willcocks; Ann M Harrington; Kirsten Zilke; Hilary Cunkle; Catherine Powers; Erika L Finanger; William D Rooney; Gihan I Tennekoon; Krista Vandenborne
Journal:  Muscle Nerve       Date:  2020-11-27       Impact factor: 3.217

4.  Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.

Authors:  Xiaonan Li; Laurie S Conklin; John van den Anker; Eric P Hoffman; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2020-05-20       Impact factor: 3.126

5.  Development of Contractures in DMD in Relation to MRI-Determined Muscle Quality and Ambulatory Function.

Authors:  Rebecca J Willcocks; Alison M Barnard; Ryan J Wortman; Claudia R Senesac; Donovan J Lott; Ann T Harrington; Kirsten L Zilke; Sean C Forbes; William D Rooney; Dah-Jyuu Wang; Erika L Finanger; Gihan I Tennekoon; Michael J Daniels; William T Triplett; Glenn A Walter; Krista Vandenborne
Journal:  J Neuromuscul Dis       Date:  2022

6.  Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance.

Authors:  Kavya S Nair; Donovan J Lott; Sean C Forbes; Alison M Barnard; Rebecca J Willcocks; Claudia R Senesac; Michael J Daniels; Ann T Harrington; Gihan I Tennekoon; Kirsten Zilke; Erika L Finanger; Richard S Finkel; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  J Neuromuscul Dis       Date:  2022

7.  MR biomarkers predict clinical function in Duchenne muscular dystrophy.

Authors:  Alison M Barnard; Rebecca J Willcocks; William T Triplett; Sean C Forbes; Michael J Daniels; Saptarshi Chakraborty; Donovan J Lott; Claudia R Senesac; Erika L Finanger; Ann T Harrington; Gihan Tennekoon; Harneet Arora; Dah-Jyuu Wang; H Lee Sweeney; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  Neurology       Date:  2020-02-05       Impact factor: 9.910

8.  Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal analysis.

Authors:  Kristin J Krosschell; Elise L Townsend; Michael Kiefer; Sarah D Simeone; Katelyn Zumpf; Leah Welty; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2021-08-24       Impact factor: 4.296

9.  Muscle architecture is associated with muscle fat replacement in Duchenne and Becker muscular dystrophies.

Authors:  Thom T J Veeger; Erik W van Zwet; Diaa Al Mohamad; Karin J Naarding; Nienke M van de Velde; Melissa T Hooijmans; Andrew G Webb; Erik H Niks; Jurriaan H de Groot; Hermien E Kan
Journal:  Muscle Nerve       Date:  2021-08-25       Impact factor: 3.852

10.  Platelet Derived Growth Factor-AA Correlates With Muscle Function Tests and Quantitative Muscle Magnetic Resonance in Dystrophinopathies.

Authors:  Alicia Alonso-Jiménez; Esther Fernández-Simón; Daniel Natera-de Benito; Carlos Ortez; Carme García; Elena Montiel; Izaskun Belmonte; Irene Pedrosa; Sonia Segovia; Patricia Piñol-Jurado; Ana Carrasco-Rozas; Xavier Suárez-Calvet; Cecilia Jimenez-Mallebrera; Andrés Nascimento; Jaume Llauger; Claudia Nuñez-Peralta; Paula Montesinos; Jorge Alonso-Pérez; Eduard Gallardo; Isabel Illa; Jordi Díaz-Manera
Journal:  Front Neurol       Date:  2021-06-11       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.